Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01012869 · ClinicalTrials.gov registry record · Phase 4
AngiographiC Evaluation of the Everolimus-Eluting Stent in Chronic Total Occlusions - the ACE-CTO Study
A Phase 4 study of Coronary Occlusions, sponsored by North Texas Veterans Healthcare System.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT01012869 is a Phase 4 study of Coronary Occlusions that has completed, run by North Texas Veterans Healthcare System. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01012869, a Phase 4 study of Coronary Occlusions, has completed, sponsored by North Texas Veterans Healthcare System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
Chronically total occlusions (CTO) are difficult to treat and have high risk for restenosis. Although everolimus-eluting stents (EES) \[(Xience, Abbott Vascular) or Promus (Boston Scientific)\] are very promising for the treatment of CTOs due to their low late loss and excellent deliverability, there are currently no published data on EES implantation in CTOs. The specific aim of this proposal is to examine the 8-month incidence of binary angiographic in-stent restenosis (defined as a stenosis of \> 50% of the minimum lumen diameter of the target stent) after implantation of the EES in CTO. It is the investigators hypothesis that EES-treated CTO lesions will have ≤ 20% 8-month in-stent binary angiographic restenosis rate.
Conditions Studied
Interventions
- DEVICE everolimus-eluting stent
Study Locations (1)
Texas
- Dallas VA Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2009-11 |
| Est. Completion | 2013-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01012869
The ClinicalTrials.gov registry entry for NCT01012869 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is North Texas Veterans Healthcare System, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Coronary Occlusions appearing as the primary indexed condition, and to 1 intervention - of which everolimus-eluting stent is the first listed.
NCT01012869 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01012869 about?
NCT01012869 is a clinical study titled "AngiographiC Evaluation of the Everolimus-Eluting Stent in Chronic Total Occlusions - the ACE-CTO Study". Chronically total occlusions (CTO) are difficult to treat and have high risk for restenosis. Although everolimus-eluting stents (EES) \[(Xience, Abbott Vascular) or Promus (Boston Scientific)\] are very promising for the treatment of CTOs due to their low late loss and excellent deliverability, ther...
What is the current status of trial NCT01012869?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2009-11. Estimated completion is 2013-06.
What conditions does trial NCT01012869 study?
This clinical trial studies the following conditions: Coronary Occlusions.
What interventions are being tested in trial NCT01012869?
The interventions under investigation include: everolimus-eluting stent (DEVICE).
Who is sponsoring clinical trial NCT01012869?
This trial is sponsored by North Texas Veterans Healthcare System, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01012869 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.